Patents Assigned to Novartis Vaccines and Diagnostics S.R.L.
-
Patent number: 8840907Abstract: Two or more Neisserial proteins are joined such that they are translated as a single polypeptide chain. Hybrid proteins are represented by the formula NH2-A-[-X-L-]n-B—COOH where X is an amino acid sequence, L is an optional linker amino acid sequence, A is an optional N-terminal amino acid sequence, B is an optional C-terminal amino acid sequence, and n is an integer greater than 1. Proteins where each of the n -X- moieties shares sequence identity to each other -X- moiety, the protein is a ‘tandem protein’.Type: GrantFiled: February 3, 2012Date of Patent: September 23, 2014Assignee: Novartis Vaccines and Diagnostics S.r.l.Inventor: Mariagrazia Pizza
-
Publication number: 20120207778Abstract: The invention provides proteins from group B streptococcus (Streptococcus agalactiae) and group A streptococcus (Streptococcus pyogenes), including amino acid sequences and the corresponding nucleotide sequences.Type: ApplicationFiled: February 16, 2012Publication date: August 16, 2012Applicants: J. CRAIG VENTER INSTITUTE, INC., NOVARTIS VACCINES AND DIAGNOSTICS S.R.L.Inventors: John Telford, Vega Masignani, Immaculada Margarit Y Ros, Guido Grandi, Claire Fraser, Hervé Tettelin
-
Patent number: 8133973Abstract: The present invention provides variant LcrE sequences and/or combinations of variant LcrE sequences across the Chlamydia trachomatis serovars. Such changes in LcrE genotypes across the Chlamydia trachomatis serovars are likely to correspond with changes in LcrE phenotypes, in particular, with changes in immunogenicity. The present invention also provides peptides surrounding or associated with the amino acid substitutions, in particular, peptides surrounding or associated with high frequency mutated amino acid positions or hypervariable regions, which are likely to be B and/or T cell epitopic regions capable of eliciting Chlamydia specific cell mediated immune responses. The variant LcrE sequences and/or combinations of the variant LcrE sequences and/or epitope regions associated with the variant LcrE sequences are useful as immunogens and/or in the preparation of immunogenic compositions for preventing and/or treating and/or, diagnosing Chlamydia infections.Type: GrantFiled: May 12, 2006Date of Patent: March 13, 2012Assignee: Novartis Vaccines and Diagnostics, S.r.l.Inventors: Guido Grandi, Giulio Ratti
-
Patent number: 8128936Abstract: The invention includes a GAS antigen, GAS 40, which is particularly suitable for use either alone or in combinations with additional GAS antigens, such as GAS 117, GAS 130, GAS 277, GAS 236, GAS 40, GAS 389, GAS 504, GAS 509, GAS 366, GAS 159, GAS 217, GAS 309, GAS 372, GAS 039, GAS 042, GAS 058, GAS 290, GAS 511, GAS 533, GAS 527, GAS 294, GAS 253, GAS 529, GAS 045, GAS 095, GAS 193, GAS 137, GAS 084, GAS 384, GAS 202, and GAS 057.Type: GrantFiled: March 2, 2010Date of Patent: March 6, 2012Assignee: Novartis Vaccines and Diagnostics, S.r.L.Inventors: Guido Grandi, John Telford, Giuliano Bensi
-
Publication number: 20110300171Abstract: The invention relates to immunization against pathogenic bacterial strains which express or can express multiple factor H binding proteins. Certain aspects of the invention include vaccine compositions comprising at least two factor H binding proteins derived from a pathogenic bacterial strain which expresses multiple facto H binding proteins.Type: ApplicationFiled: September 14, 2009Publication date: December 8, 2011Applicants: HUMANITAS MIRASOLE S.P.A., NOVARTIS VACCINES AND DIAGNOSTICS S.R.L.Inventors: Silvana Savino, John Donnelly, Rino Rappuoli, Mariagrazia Pizza, Barbara Bottazzi
-
Patent number: 7838010Abstract: Group A streptococcal (GAS) antigens useful for providing immunity against pyogenes infection.Type: GrantFiled: October 11, 2005Date of Patent: November 23, 2010Assignee: Novartis Vaccines and Diagnostics S.R.L.Inventors: Giuliano Bensi, Guido Grandi, Nathalie Norais, Manuel J. Rodriguez Ortega
-
Patent number: 7700755Abstract: This invention provides polynucleotides encoding Helicobacter pylori cytotoxin associated immunodominant antigen. The polynucleotides can be used as probes to identify the presence of complementary target nucleotide sequences. The invention also provides kits and vectors containing the polynucleotides of the invention.Type: GrantFiled: July 8, 2003Date of Patent: April 20, 2010Assignee: Novartis Vaccines and Diagnostics S. R. L.Inventors: Antonello Covacci, Massimo Bugnoli, John Telford, Giovanni Macchia, Rino Rappuoli
-
Patent number: 7657385Abstract: The extracellular loop of CD81 is a cellular receptor for the E2 protein of hepatitis C virus. A CD81 crystal structure has been elucidated and is provided for use in the structure-based design of compounds which bind to CD81 and thus block the binding of HCV. Methods such as docking and de novodrug design can be used.Type: GrantFiled: July 3, 2001Date of Patent: February 2, 2010Assignee: Novartis Vaccines and Diagnostics, S.R.L.Inventors: Martino Bolognesi, Guido Grandi
-
Publication number: 20090324633Abstract: Disclosed herein are various genes that can be included in immunogenic compositions specific for pathogenic E. coli strains. The genes are from uropathogenic strains but are absent from non-pathogenic strains, and their encoded proteins have cellular locations which render them accessible to the immune system.Type: ApplicationFiled: February 17, 2006Publication date: December 31, 2009Applicant: Novartis Vaccines and Diagnostics, S.R.L.Inventors: Maria-grazia Pizza, Laura Serino, Francesco Berlanda Scorza, Danilo Gomes Moriel, Maria Rita Fontana
-
Publication number: 20090298099Abstract: The invention provides proteins from gonococcus (Neisseria gonorrhoeae), including amino acid sequences, the corresponding nucleotide sequences, expression data, and serological data. The proteins are useful antigens for vaccines, immunogenic compositions, and/or diagnostics. They are also useful for distinguishing between gonococcus and meningococcus and, in particular, between gonococcus and serogroup B meningococcus.Type: ApplicationFiled: February 16, 2009Publication date: December 3, 2009Applicant: Novartis Vaccines and Diagnostics S.R.L.Inventors: Maria Rita FONTANA, Mariagrazia Pizza, Vega Masignani, Elisabetta Monaci
-
Publication number: 20090104218Abstract: Polypeptides and nucleic acids from Streptococcus agalactiae which can be used in the development of vaccines, for diagnostic purposes, and as targets for antibiotics.Type: ApplicationFiled: December 21, 2005Publication date: April 23, 2009Applicants: J. CRAIG VENTER INSTITUTE, NOVARTIS VACCINES AND DIAGNOSTICS, S.R.L.Inventors: Herve Tettelin, Vega Masignani
-
Patent number: 7504111Abstract: The invention provides proteins from gonococcus (Neisseria gonorrhoeae), including amino acid sequences, the corresponding nucleotide sequences, expression data, and serological data. The proteins are useful antigens for vaccines, immunogenic compositions, and/or diagnostics. They are also useful for distinguishing between gonococcus and meningococcus and, in particular, between gonococcus and serogroup B meningococcus.Type: GrantFiled: February 12, 2002Date of Patent: March 17, 2009Assignee: Novartis Vaccines and Diagnostics S.R.L.Inventors: Maria Rita Fontana, Mariagrazia Pizza, Vega Masiganani, Elisabetta Monaci
-
Patent number: 7427404Abstract: New pertussis toxin (PT) mutants are described being immunologically active and having reduced or no toxicity, characterized in that at least one of the aminoacid residues Glu129, Asp11, Trp26, Arg9, Phe50, Asp1, Arg13, Tyr130, Gly86, Ile88, Tyr89, Tyr8, Gly 44, Thr53 and Gly80 or subunit's 1 aminoacid sequence is deleted and substituted by a different aminoacid residue selected in the group of natural aminoacids; Bordetella strains capable of providing and secreting said PT mutants and means and methods for obtaining them are also described. The Bordetella strains and the PT mutants produced by them are particularly suitable for the preparation of effective cellular and acellular antipertussis vaccines. (FIG.Type: GrantFiled: June 17, 1994Date of Patent: September 23, 2008Assignee: Novartis Vaccines and Diagnostics S.R.L.Inventors: Mariagrazia Pizza, Antonello Covacci, Rino Rappuoli
-
Patent number: 7410646Abstract: Immunologically active polypeptides with no or reduced toxicity useful for the preparation of an antipertussis vaccine. Method for the preparation of said polypeptides which comprises, cultivating a microorganism transformed with a hybrid plasmid including the gene/s which codes for at least one of said polypeptides in a suitable medium and recovering the desired polypeptide from the cells or from the culture medium.Type: GrantFiled: June 17, 1994Date of Patent: August 12, 2008Assignee: Novartis Vaccines and Diagnostics S.R.L.Inventors: Mariagrazia Pizza, Antonella Bartoloni, Rino Rappuoli
-
Publication number: 20080160045Abstract: To improve the stability of vaccines comprising aluminum salt(s), the invention uses the amino acid histidine. This can improve pH stability and adjuvant adsorption and can reduce antigen hydrolysis. Histidine is preferably present during adsorption to the aluminum salt(s). The antigen in the vaccine may be a protein or a saccharide and is preferably from N. meningitidis.Type: ApplicationFiled: January 3, 2008Publication date: July 3, 2008Applicant: Novartis Vaccines and Diagnostics, s.r.l.Inventors: Mario Contorni, Massimo Maffei
-
Patent number: 7348006Abstract: To improve the stability of vaccines comprising aluminum salt(s), the invention uses the amino acid histidine. This can improve pH stability and adjuvant adsorption and can be reduce antigen hydrolysis. Histidine is preferably presen during adsorption to the aluminium salt(s). The antigen in the vaccine may be a protein or a saccharide and is preferably from N. meningitidis.Type: GrantFiled: July 26, 2002Date of Patent: March 25, 2008Assignee: Novartis Vaccines and Diagnostics, s.r.l.Inventors: Mario Contorni, Massimo Maffei
-
Patent number: 7252958Abstract: Tetraspanins have been found to dimerise. Methods for inhibiting or promoting the dimerisation of tetraspanins are provided, which may involve protein engineering of the tetraspanins themselves, or may rely on other molecules.Type: GrantFiled: July 3, 2001Date of Patent: August 7, 2007Assignee: Novartis Vaccines and Diagnostics S.R.L.Inventors: Martino Bolognesi, Guido Grandi
-
Publication number: 20060233827Abstract: An 85kDa antigen from Neisseria meningitidis and Neisseria gonorrhoeae has been cloned, sequenced and expressed. The antigen is common to diverse strains, serogroups and serotypes of N. meningitidis, and also to N. gonorrhoeae, N. polysaccharia and N. lactamica. The protein sequences of N. meningitidis (serogroups A and B) and N. gonorrhoeae are highly homologous.Type: ApplicationFiled: November 1, 2005Publication date: October 19, 2006Applicants: Novartis Vaccines and Diagnostics, S.r.l., Statens Institutt for FolkehelseInventors: Marzia Giuliani, Mariagrazia Pizza, Rino Rappuoli, Johan Holst